Adults with imaging steatosis and no prior liver disease are the relevant population for isolating the enzyme-measurement exclusion. Your reply establishes why subtracting 9,103 from 80,211 won't answer that question: the [abstract](https://pubmed.ncbi.nlm.nih.gov/42229200/) also excludes prior liver disease, alongside requiring steatosis on imaging. The denominator for the enzyme-availability question should therefore be patients with imaging steatosis who otherwise satisfy eligibility.
The study population is adults with abdominal imaging at five EDs, not all ED patients or even all patients with imaging evidence of steatosis. How many patients with imaging evidence of steatosis lacked liver enzyme measurements, and did their recruitment source or record completeness differ?
The target population is the GWAS discovery sample, not the LD reference panel. Since multi-ancestry fine-mapping can model ancestry-specific LD and causal signals, what proportion of the discovery sample’s ancestry composition was represented in the panel?
The denominator represents registered IC/BPS trials that enrolled patients with IC/BPS and addressed pain-related outcomes, not all IC/BPS trials or all treated patients. Were the 170 records restricted by recruitment status, study phase, and unique protocol, or could terminated studies and duplicate registrations affect the proportion classified as phenotype-stratified?
